Efficacy and safety of an artificial dermal graft for the reconstruction of exenterated sockets: a preliminary report

2021 ◽  
Author(s):  
B. Monjanel ◽  
S. Baillif ◽  
J. Lagier ◽  
L. Gastaud ◽  
G. Poissonnet ◽  
...  
Keyword(s):  
Preliminary Report ◽  
Efficacy And Safety ◽  
Dermal Graft

scholarly journals A Prospective Phase II Study on The Use Of Convalescent Plasma Monotherapy For The Treatment of Severe Covid-19 Disease: A Preliminary Report.

2020 ◽  
Author(s):  
Vasiliki Pappa ◽  
Marianna Politou ◽  
Sotirios G Papageorgiou ◽  
Anastasia Antoniadou ◽  
Anastasia Kotanidou ◽  
...  
Keyword(s):  
Preliminary Report ◽  
Phase Ii Study ◽  
Virus Disease ◽  
Symptomatic Improvement ◽  
Disease Course ◽  
Efficacy And Safety ◽  
Igg Antibodies ◽  
Duration Of Hospitalization ◽  
Prospective Phase

Abstract Currently, there are no effective treatments for novel corona virus disease 2019 (COVID-19). In this study, we report the preliminary results on the efficacy and safety of convalescent plasma (CP) infusion, as monotherapy in 9 patients with severe COVID-19 disease. The median time from symptom onset to CP transfusion was 6 days. All symptoms improved significantly after a median of 8 days. In 6/9 patients, symptomatic improvement was observed already after the 1st dose of CP transfusion. Laboratory parameters associated with disease severity tended to significantly decrease over time and lymphocyte counts significantly increased on day 14. All patients exhibited significant increases in SARS-CoV-2 IgA and IgG antibodies starting on day 7 through day 21 after CP infusion with concurrent reduction of SARS-CoV-2 RNA on days 7 and 14 with 44.4% % of the patients having undetectable SARS-CoV-2 RNA on day 14. After a median follow-up of 66 days, all patients remain alive. Eight patients recovered completely and were discharged from hospital after a median duration of hospitalization of 21 days. No severe adverse events were observed. In conclusion, this preliminary report suggests that CP infusion monotherapy administered early in the disease course may be a safe and effective strategy for patients with severe COVID-19 disease. Trial registration: NCT04408209. Registered 05 May 2020- Retrospectively registered, (https://clinicaltrials.gov/ct2/show/NCT04408209?term=NCT04408209&draw=2&rank=1).

Efficacy and Safety of Higher Dose Stereotactic Radiosurgery for Functional Pituitary Adenomas: A Preliminary Report

2014 ◽  
Vol 82 (1-2) ◽  
pp. 195-201 ◽  
Author(s):  
Ryan A. Grant ◽  
Margaret Whicker ◽  
Ranee Lleva ◽  
Jonathan P.S. Knisely ◽  
Silvio E. Inzucchi ◽  
...  
Keyword(s):  
Stereotactic Radiosurgery ◽  
Pituitary Adenomas ◽  
Preliminary Report ◽  
Efficacy And Safety
Sign in / Sign up

Export Citation Format

Share Document